Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Operating Margin (2020 - 2025)

Historic Operating Margin for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 226.92%.

  • Foghorn Therapeutics' Operating Margin rose 785600.0% to 226.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 352.87%, marking a year-over-year increase of 552700.0%. This contributed to the annual value of 454.31% for FY2024, which is 1383800.0% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Operating Margin stood at 226.92% for Q3 2025, which was up 785600.0% from 279.17% recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Operating Margin high stood at 97.73% for Q3 2023, and its period low was 64051.22% during Q3 2021.
  • Moreover, its 5-year median value for Operating Margin was 572.42% (2023), whereas its average is 4825.42%.
  • Its Operating Margin has fluctuated over the past 5 years, first plummeted by -537221700bps in 2021, then soared by 636252500bps in 2022.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Operating Margin stood at 3938.57% in 2021, then skyrocketed by 81bps to 762.09% in 2022, then skyrocketed by 42bps to 441.29% in 2023, then plummeted by -90bps to 840.51% in 2024, then skyrocketed by 73bps to 226.92% in 2025.
  • Its Operating Margin was 226.92% in Q3 2025, compared to 279.17% in Q2 2025 and 384.96% in Q1 2025.